Hint mode is switched on Switch off
For swift navigation between sections

Clovis Oncology
LEI 529900WCUY9ZAHMRV489

PDF download

Choose all Reset all
Download Cancel
The issuer's bonds defaulted in 2025
Organization name
Clovis Oncology, Inc
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
373 mln USD

Upgrade to Premium features

Cbonds consolidates global bond, stock, ETF and indices data into a single platform — so you can analyze faster, make informed investment decisions and outperform the market

Get access
Welcome to Cbonds

  • Full access to the largest bond database

    Bond parameters,
    prospectuses

  • Seamless
    Data export

    Analyze the data in the most efficient way

  • Bond pricing

    Current & historical quotes from 400+ stock exchanges & OTC market

  • Smart risk assessment

    Credit ratings, financial reports

Get access

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Clovis Oncology, Inc. (Clovis) is a Development-stage Company. The Company is a Biopharmaceutical Company. The Company focuses on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and additional international markets. The Company also focuses on the treatment of specific subsets of cancer populations.

Awards

News

10/07/2023 Clovis Oncology: Bankruptcy Or Receivership, Material Modifications To The Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors And Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Other Events, Financial Statements And Exhibits
30/06/2023 Clovis Oncology: Material Modifications To The Rights Of Security Holders, Regulation Fd Disclosure, Financial Statements And Exhibits
26/05/2023 Clovis Oncology: Regulation Fd Disclosure, Other Events, Financial Statements And Exhibits
02/05/2023 Clovis Oncology: Regulation Fd Disclosure, Financial Statements And Exhibits
01/05/2023 Clovis Oncology: Completion Of Acquisition Or Disposition Of Assets
All organization news

Documentation

IFRS/US GAAP reports

2022
I q eng
II q eng
III q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
I q eng
II q eng
III q eng
IV q eng
2018
I q eng
II q eng
III q eng
IV q eng
2017
I q eng
II q eng
III q eng
IV q eng
2016
I q eng
II q eng
III q eng
IV q eng
2015
I q eng
II q eng
III q eng
IV q eng
2014
IV q eng
Show all Hide
Authorization required
You need to request access

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    529900WCUY9ZAHMRV489
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001466301
Registration is required to get access.